In Brief: Block Drug's amlexanox
Block Drug's amlexanox: "Approvable" at FDA for the treatment of signs and symptoms of aphthous ulcers (canker sores) as of April 16. Amlexanox will be the first product marketed for canker sores. The NDA was filed April 17, 1995; a first NDA was filed in September 1994 but was refused because of inspection access issues. Drug codeveloper Access Pharmaceuticals of Dallas sold its rights to amlexanox in September...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth